Sage Therapeutics (FRA:SG7) Institutional Ownership : 61.20% (As of Jun. 05, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sage Therapeutics's institutional ownership is 61.20%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sage Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sage Therapeutics's Float Percentage Of Total Shares Outstanding is 88.07%.

Sage Therapeutics Institutional Ownership Historical Data

The historical data trend for Sage Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics Institutional Ownership Chart

Sage Therapeutics Historical Data

The historical data trend for Sage Therapeutics can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30
Institutional Ownership	71.73	67.80	69.28	64.27	63.15	59.83	60.71	60.19	61.85	61.20

Sage Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Sage Therapeutics (FRA:SG7) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (FRA:SG7) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

SAGE:USA SG7:Germany

Address

215 First Street, Cambridge, MA, USA, 02142

Website

https://www.sagerx.com

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.

Sage Therapeutics (FRA:SG7) Headlines

No Headlines